{
  "id": 4857534,
  "title": "Characterization and pharmacological modulation of Alzheimers disease-associated human microglial states",
  "url": "https://urgent.news/2026/09/01/characterization-and-pharmacological-modulation-of-alzheimers-disease",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-01T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.08.26.747247v1?rss=1"
  },
  "original_language": "en",
  "account": "Microglia play a crucial role in the development of Alzheimer's disease (AD), but the specific mechanisms and potential treatments for AD-associated microglial states remain unclear. Researchers have now analyzed single-nucleus transcriptomic data from AD patients, uncovering a new type of microglia called disease- and lipid-associated microglia (DLaM). This population is enriched in AD patients and is associated with genetic risk factors, brain damage, and cognitive decline.\n\nTo simulate DLaM in a lab setting, scientists tested various treatments on human-induced pluripotent stem cell (hiPSC)-derived microglia. They discovered that ferric ammonium citrate (FAC) effectively mimicked the DLaM state, leading to lipid buildup, lysosomal dysfunction, and decreased ability to clear a toxic protein called amyloid-beta (Aβ). To reverse this state, the researchers used a method called transcriptomics-based state-reversion screening, which identified a drug called LY2090314 as a promising modifier. LY2090314 helped restore normal microglial function and switched the cells into a different metabolic state that was less harmful to the brain. These findings offer a new approach for identifying potential treatments for Alzheimer's disease based on the specific state of the microglia involved.",
  "summary": "Microglia are central mediators of Alzheimers disease (AD) pathogenesis, yet the mechanisms driving disease-associated microglial states and their therapeutic modulation remain poorly understood. Here, we integrated single-nucleus transcriptomic datasets across the AD spectrum and identified disease- and lipid-associated microglia (DLaM) as a major AD-enriched population linked to genetic risk,…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}